Close Menu

NEW YORK (GenomeWeb) – Pharmaceutical firm Arcus Biosciences and precision oncology firm Strata Oncology have entered into a clinical development collaboration in which they will use Strata's biomarker technology to identify responders to Arcus' clinical-stage anti-PD-1 antibody AB122 among a variety of tumor types that don't normally show response to such drugs.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.